Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease

Sponsor
AB Science
Study ID
NCT00976118
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • masitinib (AB1010) — DRUG
    oral masitinib 3 or 6 mg/kg/day
  • placebo — DRUG
    matching placebo to masitinib

Study Details

This phase 2 study was designed to evaluate the activity of oral masitinib (AB1010) administered at 2 dose levels during 24 weeks to patients with mild to moderate confirmed Alzheimer's type disease.

Key Dates

Start date
Feb 28, 2006
Status verified
Dec 2018
Primary completion
Jul 31, 2008
Completion
Feb 28, 2009

Study Design

Enrollment
34 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: placebo
  • Experimental: oral masitinib (AB1010)
    masitinib (AB1010) 3 or 6 mg/kg/day

Primary Outcome Measure

change from baseline in ADAS-Cog [ Time Frame: week 24 ]

Related Studies